Minicircle-oriP-IFNγ: A novel targeted gene therapeutic system for EBV positive human nasopharyngeal carcinoma

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Zuo, Yufang ^a   Wu, Jiangxue ^a   Xu, Zumin ^a,c   Yang, Shiping ^a,d   Yan, Haijiao ^a   Tan, Li ^a   Meng, Xiangqi ^a   Ying, Xiaofang ^a   Liu, Ranyi ^a   Kang, Tiebang ^a   Huang, Wenlin ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; LUCIFERASE; MESSENGER RNA; MINICIRCLE DNA; PLASMID VECTOR; PROTEIN BAK; PROTEIN P21; SMALL INTERFERING RNA; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL KILLING; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; DRUG SAFETY; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GENE VECTOR; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NASOPHARYNX CANCER; NASOPHARYNX CARCINOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION REGULATION; TRANSGENE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CELL SURVIVAL; GENETICS; METABOLISM; NASOPHARYNX TUMOR; NUDE MOUSE; PATHOGENICITY; PHYSIOLOGY; PLASMID; VIROLOGY;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4; MUS MUSCULUS;

ANIMALS; CELL LINE; CELL SURVIVAL; FEMALE; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 79955813305     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019407     Document Type: Article

References (43)

1. Hine CM, Seluanov A, Gorbunova V, (2008) Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci U S A 105: 20810-20815.
2. Dorer DE, Nettelbeck DM, (2009) Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 61: 554-571.
3. Chang DK, Lin CT, Wu CH, Wu HC, (2009) A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One 4: e4171.
4. Glasgow JN, Mikheeva G, Krasnykh V, Curiel DT, (2009) A strategy for adenovirus vector targeting with a secreted single chain antibody. PLoS One 4: e8355.
5. Wu L, Johnson M, Sato M, (2003) Transcriptionally targeted gene therapy to detect and treat cancer. Trends Mol Med 9: 421-429.
6. Cohen JI, (2000) Epstein-Barr virus infection. N Engl J Med 343: 481-492.
7. Bochkarev A, Barwell JA, Pfuetzner RA, Bochkareva E, Frappier L, et al. (1996) Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell 84: 791-800.
8. Niedobitek G, Agathanggelou A, Nicholls JM, (1996) Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol 7: 165-174.
9. Altmann M, Pich D, Ruiss R, Wang J, Sugden B, et al. (2006) Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proc Natl Acad Sci U S A 103: 14188-14193.
10. Leight ER, Sugden B, (2000) EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev Med Virol 10: 83-100.
11. Lindner SE, Sugden B, (2007) The plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient, licensed, extrachromosomal replication in human cells. Plasmid 58: 1-12.
12. Li JH, Chia M, Shi W, Ngo D, Strathdee CA, et al. (2002) Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res 62: 171-178.
13. Wu J, Xiao X, Zhao P, Xue G, Zhu Y, et al. (2006) Minicircle-IFNgamma induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma. Clin Cancer Res 12: 4702-4713.
14. Wu J, Xiao X, Jia H, Chen J, Zhu Y, et al. (2009) Dynamic distribution and expression in vivo of the human interferon gamma gene delivered by adenoviral vector. BMC Cancer 9: 55.
15. Sher YP, Tzeng TF, Kan SF, Hsu J, Xie X, et al. (2009) Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival. Oncogene 28: 3286-3295.
16. Chen ZY, He CY, Ehrhardt A, Kay MA, (2003) Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 8: 495-500.
17. Judde JG, Spangler G, Magrath I, Bhatia K, (1996) Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia. Hum Gene Ther 7: 647-653.
18. Li JH, Shi W, Chia M, Sanchez-Sweatman O, Siatskas C, et al. (2003) Efficacy of targeted FasL in nasopharyngeal carcinoma. Mol Ther 8: 964-973.
19. Chia MC, Shi W, Li JH, Sanchez O, Strathdee CA, et al. (2004) A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy. Mol Ther 9: 804-817.
20. Yip KW, Li A, Li JH, Shi W, Chia MC, et al. (2004) Potential utility of BimS as a novel apoptotic therapeutic molecule. Mol Ther 10: 533-544.
21. Marshall E, (1999) Gene therapy death prompts review of adenovirus vector. Science 286: 2244-2245.
22. Jechlinger W, (2006) Optimization and delivery of plasmid DNA for vaccination. Expert Rev Vaccines 5: 803-825.
23. Chen ZY, He CY, Meuse L, Kay MA, (2004) Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther 11: 856-864.
24. Chen ZY, He CY, Kay MA, (2005) Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther 16: 126-131.
25. Chang CW, Christensen LV, Lee M, Kim SW, (2008) Efficient expression of vascular endothelial growth factor using minicircle DNA for angiogenic gene therapy. J Control Release 125: 155-163.
26. Zhang X, Epperly MW, Kay MA, Chen ZY, Dixon T, et al. (2008) Radioprotection in vitro and in vivo by minicircle plasmid carrying the human manganese superoxide dismutase transgene. Hum Gene Ther 19: 820-826.
27. Huang M, Chen Z, Hu S, Jia F, Li Z, et al. (2009) Novel minicircle vector for gene therapy in murine myocardial infarction. Circulation 120: S230-237.
28. Jia F, Wilson KD, Sun N, Gupta DM, Huang M, et al. (2010) A nonviral minicircle vector for deriving human iPS cells. Nat Methods 7: 197-199.
29. Chen ZY, Riu E, He CY, Xu H, Kay MA, (2008) Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther 16: 548-556.
30. Zhang C, Gao S, Jiang W, Lin S, Du F, et al. (2010) Targeted minicircle DNA delivery using folate-poly(ethylene glycol)-polyethylenimine as non-viral carrier. Biomaterials 31: 6075-6086.
31. Hu S, Huang M, Li Z, Jia F, Ghosh Z, et al. (2010) MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 122: S124-131.
32. Hoffman RM, (1999) Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17: 343-359.
33. Liu T, Ding Y, Xie W, Li Z, Bai X, et al. (2007) An imageable metastatic treatment model of nasopharyngeal carcinoma. Clin Cancer Res 13: 3960-3967.
34. Teng ZP, Ooka T, Huang DP, Zeng Y, (1996) Detection of Epstein-Barr Virus DNA in well and poorly differentiated nasopharyngeal carcinoma cell lines. Virus Genes 13: 53-60.
35. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, et al. (1999) Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 83: 121-126.
36. Friboulet L, Pioche-Durieu C, Rodriguez S, Valent A, Souquere S, et al. (2008) Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis. Neoplasia 10: 1183-1194.
37. Yin Q, Flemington EK, (2006) siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology 346: 385-393.
38. Sivachandran N, Sarkari F, Frappier L, (2008) Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies. PLoS Pathog 4: e1000170.
39. Fecker LF, Geilen CC, Tchernev G, Trefzer U, Assaf C, et al. (2006) Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 126: 1366-1371.
40. Zhu Y, Singh B, Hewitt S, Liu A, Gomez B, et al. (2006) Expression patterns among interferon regulatory factor-1, human X-box binding protein-1, nuclear factor kappa B, nucleophosmin, estrogen receptor-alpha and progesterone receptor proteins in breast cancer tissue microarrays. Int J Oncol 28: 67-76.
41. Wang Y, Liu DP, Chen PP, Koeffler HP, Tong XJ, et al. (2007) Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers. Cancer Res 67: 2535-2543.
42. Fauvet R, Poncelet C, Hugol D, Lavaur A, Feldmann G, et al. (2003) Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours. Virchows Arch 443: 38-43.
43. Chen X, Larson CS, West J, Zhang X, Kaufman DB, (2010) In vivo detection of extrapancreatic insulin gene expression in diabetic mice by bioluminescence imaging. PLoS One 5: e9397.